1. Clinical & Scientific Overview
Sodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis) (TIP-MED-000203, Reference Code [10.19]) is classified under
Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.19], p. 136): Sobosis / Sobosis Forte (La Renon), Nodosis / Nodosis DS (Steadfast), Sodamint — Strengths & Dosage Forms: Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
3. Mechanism of Action & Pharmacodynamics
Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022) for Correction of chronic metabolic acidosis in CKD Stage 3b–5 when Serum Bicarbonate (HCO3-) falls <18–22 mEq/L (KDIGO 2024: chronic acidosis accelerates GFR loss, causes muscle catabolism, demineralises bone, and worsens hyperkalaemia!); urinary alkalinisation.
4. Therapeutic Indications & Evidence-Supported Uses
- Correction of chronic metabolic acidosis in CKD Stage 3b–5 when Serum Bicarbonate (HCO3-) falls <18–22 mEq/L (KDIGO 2024: chronic acidosis accelerates GFR loss, causes muscle catabolism, demineralises bone, and worsens hyperkalaemia!)
- urinary alkalinisation
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: CKD Metabolic Acidosis: Start 500 mg PO BD–TDS (1.5 g/day), titrate to 500–1000 mg BD–TDS (up to 2–3 g/day) to maintain Serum Bicarbonate in the normal physiological range of 22–26 mEq/L
Administration & Meal Timing: Take 1–2 hours AFTER meals (taking uncoated Sodium Bicarbonate directly with a large meal neutralises gastric HCl, releases CO2 gas causing belching/gastric distension, and alters pH-dependent absorption of other drugs! Enteric-coated Sobosis/Nodosis EC reduces bloating) | 1–2 Hours After Breakfast, Lunch & Dinner (BD or TDS)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in metabolic or respiratory alkalosis (Serum HCO3- >28 mEq/L), severe uncontrolled hypertension, decompensated congestive heart failure / pulmonary oedema, anuric fluid overload, and hypocalcaemia. Each 1000 mg tablet delivers 274 mg of Sodium!
Key Clinical Precautions: Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
8. Adverse Effects Profile
- Abdominal bloating, belching/eructation, flatulence (markedly reduced by using Enteric-Coated tablets!), ankle oedema, mild blood pressure elevation
- Fluid overload / pulmonary oedema and worsening hypertension (from sodium load in CKD/HF), metabolic alkalosis (Serum HCO3- >28–30 mEq/L -> accelerates vascular calcification & precipitates hypocalcaemic tetany!), hypokalaemia
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- ALTERS GI pH AND URINARY pH: (1) Raises gastric pH -> reduces absorption of Oral Iron, Ketoconazole/Itraconazole, Cefuroxime/Cefpodoxime, and causes premature gastric dissolution of Enteric-Coated Bisacodyl or Mesalazine (separate by >=2 hours from all other oral medicines!); (2) Alkalinises urine -> increases renal excretion of Lithium and Salicylates/Methotrexate, and decreases excretion of Memantine/Quinidine
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Protects your kidneys, muscles, and bones from acid buildup in CKD; take 1–2 hours after meals and space at least 2 hours apart from Iron, Calcium, or other tablets; reduce added salt in your cooking and monitor your blood pressure and ankle swelling
- Meal & Clock Timing Instruction: Take 1–2 hours AFTER meals (taking uncoated Sodium Bicarbonate directly with a large meal neutralises gastric HCl, releases CO2 gas causing belching/gastric distension, and alters pH-dependent absorption of other drugs! Enteric-coated Sobosis/Nodosis EC reduces bloating) (1–2 Hours After Breakfast, Lunch & Dinner (BD or TDS))
- Missed Dose Protocol: Take 1–2 hours after next meal if remembered; do not double dose
- Geriatric Dispensing Pearl: Monitor blood pressure and fluid status (ankle oedema/dyspnoea) closely in older CKD patients with concurrent heart failure
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.19] (p. 136)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.14] Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism) — Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalcif
- [10.18] Oral Potassium Chloride & Potassium Citrate Solutions — Electrolyte Replenishment & Urinary Alkalinising / Citrate-Chelat
- [10.20] Sevelamer Carbonate & Calcium Polystyrene Sulfonate / Sodium Zirconium Cyclosilicate — Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassi
- [10.14]-C119 Alfacalcidol — Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalcif